NeoGenomics is a diagnostics & research business based in the US. NeoGenomics shares (NEO.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $14.14 – an increase of 2.09% over the previous day. NeoGenomics employs 2,100 staff and has a trailing 12-month revenue of around $591.6 million.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $11.03 up to $21.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 1.098. This would suggest that NeoGenomics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Historical closes compared with the last close of $14.14
| 1 week (2024-04-18) | 4.51% |
|---|---|
| 1 month (2024-03-26) | -6.97% |
| 3 months (2024-01-25) | -9.42% |
| 6 months (2023-10-26) | 3.89% |
| 1 year (2023-04-26) | -1.12% |
| 2 years (2022-04-26) | 35.44% |
| 3 years (2021-04-26) | -72.26% |
| 5 years (2019-04-25) | -30.92% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the NeoGenomics P/E ratio, PEG ratio and EBITDA
NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Steps to owning and managing IOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing UDMY, with 24-hour and historical pricing before you buy.
Steps to owning and managing RELY, with 24-hour and historical pricing before you buy.
Steps to owning and managing GNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing JOB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing VVNT, with 24-hour and historical pricing before you buy.
Steps to owning and managing DXCM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CERN, with 24-hour and historical pricing before you buy.